Bojadzic D et al., 2021-01-13: The paper the BluZone documents cite for the COVID claim. It is a peer-reviewed in vitro study showing methylene blue blocks the spike-ACE2 protein interaction with an IC50 of about 3 micromolar, and blocks pseudovirus entry with a similar IC50. It measures binding inhibition, not elimination of virus, and reports no time-to-elimination.
We confirmed that it does so in a concentration-dependent manner with a low micromolar half-maximal inhibitory concentration (IC50 = 3 uM) in our protein-based ELISA-type setup
Bojadzic D et al., 2021-01-13: The paper the BluZone documents cite for the COVID claim. It is a peer-reviewed in vitro study showing methylene blue blocks the spike-ACE2 protein interaction with an IC50 of about 3 micromolar, and blocks pseudovirus entry with a similar IC50. It measures binding inhibition, not elimination of virus, and reports no time-to-elimination. Study type: in vitro biochemical assay (ELISA-type protein-protein interaction) plus pseudovirus entry assay. N/A (no human or animal subjects). Country: USA (University of Miami, Diabetes Research Institute). Concentration: IC50 3 uM (binding), 3.5 uM (pseudovirus entry). No light used. Comparator: chloroquine, siramesine and suramin showed no inhibitory activity in the same assay. Funder/conflicts: authors declare no commercial or financial conflicts. First posted as a bioRxiv preprint (doi 10.1101/2020.08.29.273441) and later published in Frontiers in Pharmacology 11:600372. It does not support a 'two minutes' claim. Study type: lab.
